P
PharmaBio
PharmaBio develops and manufactures regenerative medicine products
About PharmaBio
PharmaBio Corporation is a Contract Development and Manufacturing Organization (CDMO) specializing in cell and tissue-based therapies in Japan. The company focuses on the development and manufacturing of regenerative medicines, leveraging its advanced technology and expertise to contribute to a better quality of life and a brighter future. PharmaBio serves clients in the healthcare and biotechnology sectors, providing high-quality services for the development and production of innovative therapies. Operating within the Japanese market, PharmaBio's business model revolves around contract manufacturing and development, where it earns revenue by offering specialized services to companies looking to develop and produce regenerative medicine products. The company is committed to maintaining high standards in its processes and systems, ensuring the delivery of advanced therapeutic solutions.
Source: Dealroom company dataAt a glance
- Headquarters
- Tokyo, Japan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
- TNTNP
UTEC - The University of Tokyo Edge Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PharmaBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PharmaBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.